EP1496881A4 - Compositions de chrome et procedes de leur utilisation afin d'inhiber la resistance a l'insuline d'origine medicamenteuse - Google Patents

Compositions de chrome et procedes de leur utilisation afin d'inhiber la resistance a l'insuline d'origine medicamenteuse

Info

Publication number
EP1496881A4
EP1496881A4 EP03747276A EP03747276A EP1496881A4 EP 1496881 A4 EP1496881 A4 EP 1496881A4 EP 03747276 A EP03747276 A EP 03747276A EP 03747276 A EP03747276 A EP 03747276A EP 1496881 A4 EP1496881 A4 EP 1496881A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
insulin resistance
induced insulin
inhibiting drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03747276A
Other languages
German (de)
English (en)
Other versions
EP1496881A2 (fr
Inventor
Vijaya Juturu
James R Komorowski
Gail Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Nutrition 21 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC
Publication of EP1496881A2 publication Critical patent/EP1496881A2/fr
Publication of EP1496881A4 publication Critical patent/EP1496881A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
EP03747276A 2002-04-23 2003-04-03 Compositions de chrome et procedes de leur utilisation afin d'inhiber la resistance a l'insuline d'origine medicamenteuse Withdrawn EP1496881A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37584802P 2002-04-23 2002-04-23
US375848P 2002-04-23
PCT/US2003/010717 WO2003090671A2 (fr) 2002-04-23 2003-04-03 Compositions de chrome et procedes de leur utilisation afin d'inhiber la resistance a l'insuline d'origine medicamenteuse

Publications (2)

Publication Number Publication Date
EP1496881A2 EP1496881A2 (fr) 2005-01-19
EP1496881A4 true EP1496881A4 (fr) 2007-04-04

Family

ID=29270708

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03747276A Withdrawn EP1496881A4 (fr) 2002-04-23 2003-04-03 Compositions de chrome et procedes de leur utilisation afin d'inhiber la resistance a l'insuline d'origine medicamenteuse

Country Status (7)

Country Link
US (1) US20050214384A1 (fr)
EP (1) EP1496881A4 (fr)
JP (1) JP2005525401A (fr)
AU (1) AU2003226313A1 (fr)
CA (1) CA2480268A1 (fr)
MX (1) MXPA04010392A (fr)
WO (1) WO2003090671A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235261A1 (en) * 2002-05-14 2003-11-11 Nipro Corporation Medicine for prevention of and treatment for amyloidosis
JP4896501B2 (ja) * 2004-11-26 2012-03-14 第一三共株式会社 血中遊離脂肪酸低下作用を有する医薬組成物
JP5045879B2 (ja) * 2006-06-07 2012-10-10 株式会社龍泉堂 インスリン抵抗性の改善効果、体重増加の抑制効果、及び脂肪肝の予防及び改善効果を有する混合物
CA3021932C (fr) * 2007-01-31 2020-12-15 Jds Therapeutics, Llc Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques
CA2681158C (fr) 2007-03-13 2018-09-18 Nutrition 21, Inc. Procedes et compositions utilises pour la liberation prolongee de chrome
WO2009002867A2 (fr) 2007-06-26 2008-12-31 Nutrition 21, Inc. Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
TWI454221B (en) * 2008-07-14 2014-10-01 Composition and method for inhibiting formation of body fat
CA2828572C (fr) 2011-03-01 2021-02-23 Jds Therapeutics, Llc Compositions d'insuline et de chrome pour traitement et prevention du diabete, de l'hypoglycemie et de troubles associes
EP3936133A1 (fr) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
JP2017523138A (ja) 2014-07-29 2017-08-17 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 経皮クリーム
US20160220581A1 (en) * 2015-01-30 2016-08-04 Jds Therapeutics, Llc Chromium compositions for the treatment or prevention of diabetic retinopathy
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0016496A1 (fr) * 1979-03-19 1980-10-01 THE PROCTER & GAMBLE COMPANY L'acétylacétonate de chrome comme supplément diététique et agent pharmaceutique
WO1989010357A1 (fr) * 1988-04-26 1989-11-02 The William Seroy Group Matiere synthetique au chrome a facteur de tolerance du glucose (gtf) et procede de production
WO1999007387A1 (fr) * 1997-08-08 1999-02-18 Nutrition 21 Traitement au chrome/biotine du diabete de type ii
WO2000015211A2 (fr) * 1998-09-17 2000-03-23 Akesis Pharmaceuticals, Inc. Compositions et traitements contre les troubles du metabolisme du glucose
WO2002004024A1 (fr) * 2000-06-30 2002-01-17 Rieveley Robert B Composition destinee au traitement du diabete

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33988E (en) * 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US4954492A (en) * 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5175156A (en) * 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US5087624A (en) * 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US6329361B1 (en) * 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
AU2002232471A1 (en) * 2000-10-31 2002-05-15 Nutrition 21, Inc. Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0016496A1 (fr) * 1979-03-19 1980-10-01 THE PROCTER & GAMBLE COMPANY L'acétylacétonate de chrome comme supplément diététique et agent pharmaceutique
US4923855A (en) * 1983-07-08 1990-05-08 The William Seroy Group Synthetic GTF chromium material and process therefor
WO1989010357A1 (fr) * 1988-04-26 1989-11-02 The William Seroy Group Matiere synthetique au chrome a facteur de tolerance du glucose (gtf) et procede de production
WO1999007387A1 (fr) * 1997-08-08 1999-02-18 Nutrition 21 Traitement au chrome/biotine du diabete de type ii
WO2000015211A2 (fr) * 1998-09-17 2000-03-23 Akesis Pharmaceuticals, Inc. Compositions et traitements contre les troubles du metabolisme du glucose
WO2002004024A1 (fr) * 2000-06-30 2002-01-17 Rieveley Robert B Composition destinee au traitement du diabete

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAVINA A ET AL.: "Reversal of corticosteroid-induced diabetes mellitis with supplemental chromium", DIABETIC MEDICINE, vol. 16, 1999, pages 164 - 167, XP002421300 *
RAVINA ALEXANDER ET AL.: "Control of steroid induced diabetes with supplemental Chromium", THE JOURNAL OF TRACE ELEMENTS IN EXPERIMENTAL MEDICINE, vol. 12, 1999, pages 375 - 378, XP002421301 *

Also Published As

Publication number Publication date
AU2003226313A1 (en) 2003-11-10
WO2003090671A2 (fr) 2003-11-06
AU2003226313A8 (en) 2003-11-10
MXPA04010392A (es) 2005-08-18
EP1496881A2 (fr) 2005-01-19
US20050214384A1 (en) 2005-09-29
JP2005525401A (ja) 2005-08-25
WO2003090671A3 (fr) 2004-09-10
CA2480268A1 (fr) 2003-11-06

Similar Documents

Publication Publication Date Title
AU2003226313A8 (en) Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
AU2003220205A8 (en) Ethanol-diesel fuel composition and methods thereof
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
AP2089A (en) Compositions and methods for combination antiviraltherapy
ZA200509086B (en) Fuel composition
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
EP1617807A4 (fr) 1,4-diazepines substituees et leurs utilisations
EG24579A (en) Herbicide composition and weed-controlling method using the same
HK1117185A1 (en) Electrocoat composition imparting sweat resistance and method for using the same
EP1726008A4 (fr) Analogue de bis-propylamine et composition
GB2393963B (en) Sliding composition and sliding member
HUP0500871A3 (en) 5-aryltetrazole compounds, compositions thereof and their use
EP1684771A4 (fr) Composition et procede associe
EP1508340A4 (fr) Agents renforcateurs de la resistance a l'insuline
AU2003254483A8 (en) Fuel composition
HU0303778D0 (en) Plant with increased drought resistance
GB0222344D0 (en) Graded particulate composition
GB0211241D0 (en) Sliding tee
GB2407579B (en) Sliding composition and sliding member
GB0420894D0 (en) Compounds and uses 2
GB0311166D0 (en) Composition and use
GB0325238D0 (en) Composition and use
GB0311163D0 (en) Composition and use
GB0311167D0 (en) Composition and use
GB0325241D0 (en) Composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041109

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20070222BHEP

Ipc: A61K 31/13 20060101ALI20070222BHEP

Ipc: A61K 33/24 20060101AFI20070222BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070305

17Q First examination report despatched

Effective date: 20071116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101101